Recursion Pharmaceuticals Inc. Class A share price logo

Recursion Pharmaceuticals Inc. Class A

NASDAQ: RXRX

Mid Cap

$3.56

-0.20

(-5.32%)

as on

Recursion Pharmaceuticals Inc. Class A Stock Performance

as on July 11, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $3.44
    $3.80
    downward going graph

    3.37%

    Downside

    6.74%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $2.77
    $7.18
    downward going graph

    22.19%

    Downside

    101.69%

    Upside

    downward going graph

Recursion Pharmaceuticals Inc. Class A share price movements today

Previous Close
$3.76
Open
$3.80
Volume
20.9M
Day's Low - High
$3.44 - $3.80
52 Week Low - High
$2.77 - $7.18

Recursion Pharmaceuticals Inc. Class A Historical Returns

1 Month Return
+ 13.02 %
3 Month Return
+ 8.54 %
1 Year Return
-32.58 %
3 Year Return
-47.49 %
5 Year Return
-91.13 %

Recursion Pharmaceuticals Inc. Class A Stock Fundamentals & Key Indicators

Check Recursion Pharmaceuticals Inc. Class A market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$2.0B

EPS (TTM)

-0.9183

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-501.2M

Revenue (TTM)

66.4M

Profit Margin

0.00%

Return On Equity TTM

-57.16%

Recursion Pharmaceuticals Inc. Class A vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Recursion Pharmaceuticals Inc. Class A with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Recursion Pharmaceuticals Inc. Class A image
Recursion Pharmaceuticals Inc. Class A
BUY$2.0B-91.13%NA0.00%NA
Alnylam Pharmaceuticals Inc. image
Alnylam Pharmaceuticals Inc.
BUY$41.8B69.04%81.2412.55%NA
Vertex Pharmaceuticals Inc. image
Vertex Pharmaceuticals Inc.
BUY$126.0B144.95%29.5935.51%NA
Regeneron Pharmaceuticals Inc. image
Regeneron Pharmaceuticals Inc.
BUY$70.0B14.49%16.1829.65%0.54%

Stock Returns calculator for Recursion Pharmaceuticals Inc. Class A Stock including INR - Dollar returns

The Recursion Pharmaceuticals Inc. Class A stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Recursion Pharmaceuticals Inc. Class A investment value today

Current value as on today

₹74,923

Returns

-₹25,077

(-25.08%)

Returns from Recursion Pharmaceuticals Inc. Class A Stock

-₹32,576 (-32.58%)

Dollar Impact

₹7,499 (+7.5%)

Analyst Recommendation on Recursion Pharmaceuticals Inc. Class A Stock

Based on 13 analysts

BUY

53.85%

Buy

46.15%

Hold

0.00%

Sell

Based on 13 analysts, 53.85% of analysts recommend a 'BUY' rating for Recursion Pharmaceuticals Inc. Class A. Average target price of $7.25

Recursion Pharmaceuticals Inc. Class A Share Price Target

Get share price movements and forecasts by analysts on Recursion Pharmaceuticals Inc. Class A.

What analysts predicted

50.9%UPSIDE

Target Price

$7.25

Current Price

$3.56

Analyzed by

13 Analysts

Target

$7.25

Recursion Pharmaceuticals Inc. Class A target price $7.25, a slight upside of 50.9% compared to current price of $3.56. According to 13 analysts rating.

Indian Investors' Interest in Recursion Pharmaceuticals Inc. Class A Stock

Investment in Recursion Pharmaceuticals Inc. Class A Shares on INDmoney has dropped by -49.01% in the last 30 days, indicating reduced investment activity.

Time period: to

Change:-49.01% versus previous 30 day period

Search interest for Recursion Pharmaceuticals Inc. Class A Stock has decreased by -18% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-18% versus previous 30 day period

Recursion Pharmaceuticals Inc. Class A Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
10
13
14
26
4
14
19
5
35
6
Gross Profit
0
2
5
14
-8
-7
-1
-24
8
-6
Operating Income
-98
-96
-100
-98
-183
-191
-176
-172
-108
-128
EBITDA
-89
-84
-88
-87
-165
-182
-147
-141
-88
-102
Interest Expense
0
0
0
0
0
0
0
0
0
0
Depreciation
7
7
8
7
12
19
23
21
19
19
Income Before Tax
-97
-92
-98
-95
-178
-202
-171
-162
-108
-122
Income Tax Expense
-4
0
0
0
0
0
-
0
0
-4
Net Income
-92
-91
-97
-95
-178
-202
-171
-162
-108
-117
Net Profit Margin
-875.34%
-677.29%
-677.17%
-366.82%
-3965.99%
-1373.26%
-899.84%
-3135.32%
-304.25%
-1815.57%

Recursion Pharmaceuticals Inc. Class A Annual Profit & Loss

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
1
3
10
39
43
58
74
Gross Profit
-44
3
10
-8
1
13
-46
Operating Income
-62
-84
-182
-245
-350
-479
-648
EBITDA
-58
-81
-174
-233
-307
-426
-559
Interest Expense
0
1
2
0
0
1
1
Depreciation
3
4
8
11
20
36
83
Income Before Tax
-61
-87
-186
-239
-332
-464
-644
Income Tax Expense
0
0
-8
0
-4
-1
0
Net Income
-62
-87
-178
-239
-328
-463
-644
Net Profit Margin
-3654.30%
-2549.25%
-1780.74%
-603.36%
-747.71%
-788.02%
-863.35%

Recursion Pharmaceuticals Inc. Class A Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
-91
-97
-95
-178
-202
-171
-162
-108
-117
Operating Cash Flow
-102
-82
-59
-115
-131
-76
-117
-46
-81
Investing Cash Flow
-6
-4
-4
275
-7
-5
-2
-1
0
Financing Cash Flow
13
263
16
10
40
97
251
132
-3
Change in Cash
-95
176
-46
167
-93
24
133
86
-87

Recursion Pharmaceuticals Inc. Class A Annual Cash Flow

All numbers in Millions USD

Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-87
-186
-239
-328
-463
-644
Operating Cash Flow
-45
-158
-83
-287
-359
-371
Investing Cash Flow
-8
-271
193
-10
260
-16
Financing Cash Flow
246
458
154
140
304
521
Change in Cash
191
28
263
-157
201
150

Global Institutional Holdings in Recursion Pharmaceuticals Inc. Class A

Funds
Holdings
Novo A/S
2.21%
UBS Group AG
0.96%
Susquehanna International Group, LLP
0.8%
Vanguard Portfolio Management, LLC
4.29%
Northern Trust Corp
0.75%
See all

Recursion Pharmaceuticals Inc. Class A News & Key Events

  • img

    Today's Timeline - 23 February

    Mon, 05:41 PM

    -

    Nvidia exits its investment in Recursion while ARK Invest increases its stake; Recursion secures $30 million milestone payment.

    Mon, 06:30 PM

    -

    Recursion to be featured in NVIDIA GTC Lightning Talk, showcasing advancements in AI-driven drug discovery.

Insights on Recursion Pharmaceuticals Inc. Class A

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, RXRX stock has moved up by 23.7%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Regeneron Pharmaceuticals, Inc. Common Stock has given 19.3% return, outperforming this stock by 53.5%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Recursion Pharmaceuticals, Inc. Class A Common Stock has experienced a drawdown of -47.9%, however Alnylam Pharmaceuticals, Inc. Common Stock resisted the overall trend and outperformed by 42.9%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 35.53M → 6.47M (in $), with an average decrease of 81.8% per quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -108.12M → -117.50M (in $), with an average decrease of 8.7% per quarter

About Recursion Pharmaceuticals Inc. Class A

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
OrganisationRecursion Pharmaceuticals Inc. Class A
Headquarters41 South Rio Grande Street, Salt Lake City, UT, United States, 84101
IndustryBiotechnology
CEODr. Najat Khan Ph.D.
E-voting on sharesClick here to vote

Key Management of Recursion Pharmaceuticals Inc. Class A

Name

Title

Ms. Erica Fox

Chief People and Impact Officer

Mr. Matthew Kinn M.B.A.

Chief Business Officer

Dr. Najat Khan Ph.D.

CEO, President & Director

Mr. Ben R. Taylor

CFO & President of Recursion UK

Mr. Benjamin Mabey M.S.

Chief Technology Officer

Mr. Ryan Kelly

Chief Communications Officer

Ms. Kristen Rushton M.B.A.

Chief Operating Officer

Dr. David Hallett Ph.D.

Chief Scientific Officer

Mr. Nathan Hatfield J.D., M.B.A.

Chief Legal Officer & Corporate Secretary

Mr. Sid Jain

Senior Vice President of Clinical Development & Data Science

FAQs

What is Recursion Pharmaceuticals Inc. Class A share price today?

Recursion Pharmaceuticals Inc. Class A share price today is $3.56 as on at the close of the market. Recursion Pharmaceuticals Inc. Class A share today touched a day high of $3.80 and a low of $3.44.

What is the 52 week high and 52 week low for Recursion Pharmaceuticals Inc. Class A share?

Recursion Pharmaceuticals Inc. Class A share touched a 52 week high of $7.18 on and a 52 week low of $2.77 on . Recursion Pharmaceuticals Inc. Class A stock price today i.e. is closed at $3.56,which is 50.42% down from its 52 week high and 28.52% up from its 52 week low.

What is Recursion Pharmaceuticals Inc. Class A's market capitalisation today?

Recursion Pharmaceuticals Inc. Class A market capitalisation is $0.00T as on .

How to invest in Recursion Pharmaceuticals Inc. Class A Stock (RXRX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Recursion Pharmaceuticals Inc. Class A on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Recursion Pharmaceuticals Inc. Class A Shares that will get you 0.4213 shares as per Recursion Pharmaceuticals Inc. Class A share price of $3.56 per share as on July 11, 2026 at 8:45 am IST.

What is the minimum amount required to buy Recursion Pharmaceuticals Inc. Class A Stock (RXRX) from India?

Indian investors can start investing in Recursion Pharmaceuticals Inc. Class A (RXRX) shares with as little as ₹95.37 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹953.70 in Recursion Pharmaceuticals Inc. Class A stock (as per the Rupee-Dollar exchange rate as on ). Based on Recursion Pharmaceuticals Inc. Class A share’s latest price of $3.56 as on July 11, 2026 at 8:45 am IST, you will get 2.8090 shares of Recursion Pharmaceuticals Inc. Class A. Learn more about fractional shares .

What are the returns that Recursion Pharmaceuticals Inc. Class A has given to Indian investors in the last 5 years?

Recursion Pharmaceuticals Inc. Class A stock has given -91.13% share price returns and 28.19% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?